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Cardiovascular disease (CVD) is highly prevalent in chronic
kidney disease, suggesting that molecules retained in uremia
might contribute to this increased risk. We explored the
relationship between p-cresol, a protein-bound uremic
retention solute, and CVD by comparing the strength of this
relationship relative to traditional and novel cardiovascular
risk factors. Univariate Cox proportional hazard analysis
showed that the free serum p-cresol concentration was
significantly associated with CVD when the primary end
point was the time to the first cardiovascular event. In
multivariate analysis, free p-cresol was significantly
associated with CVD in non-diabetics. In diabetic patients,
however, a significant relationship between p-cresol and
cardiovascular events could not be demonstrated despite
their having significantly higher p-cresol levels. Our study
shows that free p-cresol is a novel cardiovascular risk factor in
non-diabetic hemodialysis patients.
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Mounting data point to the lethal synergy between chronic
kidney disease (CKD) and cardiovascular disease (CVD).1–5
Traditional cardiovascular risk factors are insufficient to
predict true cardiovascular risk in patients with CKD.6,7
Novel risk factors include the C-reactive protein (CRP) as a
marker of inflammation, a disturbed mineral metabolism,
albumin, and anemia.8–12 Uremic retention solutes have been
implicated in the pathogenesis of accelerated atherosclerosis
as well.13–17
In recent years, the focus of the nephrology community is
shifting toward protein-bound uremic retention solutes.18
The HEMO and adequacy of dialysis Mexico studies19,20
failed to show an improvement of patient outcome by
increasing the removal of water soluble solutes above
the current standards of care. The clinical importance of
protein-bound uremic retention solutes is underscored by
a recent observational study in hemodialysis patients in
which we demonstrated that p-cresol, a prototypic uremic
protein-bound retention solute, is independently associated
with overall mortality.21
In vitro evidence suggests a deleterious effect of p-cresol
on the endothelium.22–24 The association between the
protein-bound uremic retention solute p-cresol and CVD
in vivo has not been investigated. The aims of this post hoc
analysis of the p-cresol mortality study21 were first to explore
the relationship between p-cresol and CVD and second to
compare the strength of this relationship relative to
traditional and novel cardiovascular risk factors.
RESULTS
Study population
One hundred and seventy-five patients were included in the
final analysis. Table 1 represents the demographic and
baseline characteristics of the study population.
Relation between p-cresol and other parameters
The concentration of unbound p-cresol correlated signifi-
cantly with age (R¼ 0.26, P¼ 0.0004), total calcium
concentration (R¼ 0.21, P¼ 0.004), dialysis vintage
(R¼ 0.23, P¼ 0.002), urea (R¼ 0.38, Po0.001), single pool
Kt/V (spKt/V) (R¼ 0.19, P¼ 0.017), and nPNA (normalized
protein nitrogen appearance) (R¼ 0.41, Po0.001) but not
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with smoking habit, body mass index, cholesterol concentra-
tion, CRP, albumin concentration, or the calcium phos-
phorus product. Patients with diabetes had significantly
higher free p-cresol concentrations (analysis of variance
(ANOVA), P¼ 0.0069) (Figure 1) as well as significantly
higher total p-cresol concentrations (ANOVA, P¼ 0.019).
Patients treated by hemodialysis had significantly higher free
p-cresol concentrations (ANOVA, P¼ 0.0008) as well as
significantly higher total p-cresol concentrations (ANOVA,
P¼ 0.023) than those treated by hemodiafiltration.
Event analysis
After a mean follow-up of 56.2 months (s.d. 5.5, median 60.1,
minimum–maximum 48.1–60.1 months), 78 patients reached
the combined primary end point of a new cardiovascular
event or death due to CVD. In univariate analysis, age,
diabetes, CRP, albumin, systolic blood pressure, and free
p-cresol were significantly (Po0.05) associated with the
primary end point (Table 2). Figure 2 shows the Kaplan–-
Meier curves of patients with free p-cresol concentrations
above and below the median (1.97 mg l1). More patients had
new fatal or non-fatal cardiovascular events in the group with
high free p-cresol concentrations (log rank, P¼ 0.022).
A multivariate model was constructed to compare the
observed association between p-cresol and CVD with a set of
novel and traditional cardiovascular risk factors. All cardio-
vascular risk factors significant at the Pp0.2 level on
univariate analysis (age, diabetes, treatment modality, systolic
blood pressure, albumin, calcium, CRP, and free p-cresol)
were included. In this model, age, diabetes, and CRP were
found to be independently associated with CVD (Table 3).
As patients with diabetes have a significantly higher
concentration of p-cresol, we performed grouped multi-
variate analyses of the patients with and without diabetes. In
the group of non-diabetics, p-cresol as a continuous variable
surpassed blood pressure, albumin, treatment modality, and
calcium and was the last variable to be eliminated from the
model. As a binary variable, besides age and CRP, p-cresol is
the only other variable to remain in the model. Figure 2b
shows the Kaplan–Meier estimate of patients without diabetes
(log rank, P¼ 0.019).
Residual renal function (RRF) was not significantly
associated with CVD in univariate analysis (Table 2). When
RRF was forced into multivariate analysis, the observed
relationship between p-cresol and CVD remained identical
(data not shown).
DISCUSSION
The main finding of this study was that higher free p-cresol
concentrations are associated with CVD in hemodialysis
patients. This association persisted after adjustment for
several covariates, including age and CRP, but was lost after
adjustment for diabetes.
Cardiovascular mortality in CKD patients treated by
hemodialysis is more than fivefold higher than in the general
population, even after stratification for age, sex, race, and the
presence of diabetes. Traditional cardiovascular risk factors
are insufficient to accurately predict cardiovascular risk in
patients with CKD.7 Survival bias may disrupt the relation-
ship between traditional risk factors and CVD.25 Besides the
traditional risk factors, an ever expanding list of novel
cardiovascular risk factors has been proposed to contribute to
the cardiovascular burden in CKD.7–12 This is the first in vivo
study to investigate the relationship between protein-bound
uremic retention solutes, of which p-cresol is a prototypic
representative, and CVD. In this study population, the
strength of the association between p-cresol and CVD
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Figure 1 | Box plot of free p-cresol concentrations in patients with
and without diabetes.
Table 1 | Main demographic, clinical, and biochemical
characteristics of study population
Age (years, median (range)) 64.7 (26–89)
Sex (male/female (%)) 108/67 (62/38)
Dialysis vintage (months, median (range)) 29.8 (2.3–158.1)
spKt/V 1.64 (0.53)
rKt/V 0.06 (0.13)
nPNA (g kg1 day1) 0.93 (0.26)
BMI (kg m2) 23.9 (4.9)
Blood pressure (systolic/diastolic (mm Hg)) 143 (19)/71 (11)
Diabetes (yes/no (%)) 52/123 (29.7/70.3)
Current smoker (yes/no/unknown (%)) 31/129/15 (18/74/8)
Cholesterol (mg per 100 ml)a 166.9 (32.0)
LDL (mg per 100 ml)a 92.8 (26.9)
Albumin (mg l1) 36.4 (3.9)
PTH (ng l1) 126.4 (177.5)
Calcium (mg per 100 ml) 9.5 (0.8)
Phosphate (mg per 100 ml) 4.8 (1.6)
Calciumphosphate (mg2 per 100 ml2) 45.9 (15.7)
Urea (mg per 100 ml) 142.4 (39.7)
b2-Microglobulin (mg l
1) 27.7 (10.6)
CRP (mg l1) 21.8 (34.4)
Total p-cresol (mg l1) 19.0 (11.9)
Free p-cresol (mg l1) 2.59 (2.25)
BMI, body mass index; CRP, C-reactive protein; LDL, low-density lipoprotein; nPNA,
normalized protein nitrogen appearance; PTH, parathyroid hormone; rKt/V, residual
Kt/V; spKt/V, single pool Kt/V.
Data are expressed as mean (s.d.), unless otherwise stated.
aOne patient missing baseline data.
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surpassed several accepted novel risk factors, including
markers of the calcium phosphate metabolism, albumin,
and hemoglobin.
We selected an overall model including the most relevant
traditional and novel risk factors based on univariate analysis.
In this model, p-cresol was not significantly associated with
the primary end point. Most possibly, adjustment for potent
modifiers of cardiovascular risk, including age and diabetes,
obscures less potent but still relevant cardiovascular risk
factors, especially in smaller cohorts.26,27 As diabetic patients
have significantly higher p-cresol concentrations, we per-
formed grouped Cox proportional hazard analyses of patients
with and without diabetes. In non-diabetics, p-cresol was
significantly associated with CVD (P¼ 0.023), whereas
treatment modality, blood pressure, calcium, and albumin
were not associated.
Although not associated with the primary end point in
univariate analysis, RRF was considered a potential con-
founder. Indeed, RRF was found to be an important
predictor of outcome in hemodialysis patients.28 We have
previously shown that especially in peritoneal dialysis
patients, RRF contributes importantly to the total clearance
of p-cresol.29 In multivariate analysis, the observed relation-
ship between p-cresol and CVD remained identical when
RRF was taken into account. A potential explanation is that
the contribution of RRF to p-cresol clearance in hemodialysis
patients is limited.30
The causes underlying the observed association between
p-cresol and CVD are not fully elucidated. As shown before,
p-cresol can be considered a representative of a larger group of
protein-bound uremic retention solutes.31 Several molecules
of this group have been shown to have deleterious effects on
the endothelium in vitro.23,32–34 In addition, p-cresol and/or
its sulfate conjugate potentially exert direct effects on the
cardiovascular system. Faure et al.24 have shown that p-cresol
induces shedding of endothelial microparticles in vitro, which
in turn are associated with endothelial dysfunction in
patients with end-stage renal failure.35 Moreover, p-cresol
inhibits endothelial cell proliferation and alters endothelial
barrier function.22,23 Although these in vitro studies clearly
demonstrated the toxic potential of p-cresol, several groups
independently have demonstrated that in vivo p-cresol largely
circulates in the form of its conjugate p-cresyl sulfate.36–38
The effects of p-cresol and p-cresyl sulfate may well be not
alike or even be completely different. This is underscored by
the observation that p-cresyl sulfate, but not p-cresol, has a
proinflammatory effect on leukocytes in vitro.39 This under-
mines the traditional view that sulfate conjugation is a mere
detoxification step. In this study, p-cresol, including con-
jugated metabolites, was measured.
Several conditions should ideally be met before any factor
can be considered as a novel cardiovascular risk factor.7 With
respect to p-cresol, most criteria seem to be fulfilled. First,
several mechanisms point to a deleterious effect of either
Table 2 | Univariate Cox proportional HR analysis for association of baseline values with time to first cardiovascular event
Variable Unit of increase HR P-value
Sex Male vs female 0.90 (0.57–1.40) NS
Age (years) 1 year 1.04 (1.02–1.06) o0.001
Diabetes Present vs absent 2.27 (1.44–3.58) 0.0004
Smoking Yes vs no 1.08 (0.57–2.00) NS
Dialysis vintage 1 month 1.00 (1.00–1.01) NS
Treatment modality HDF vs HD 0.68 (0.42–1.10) 0.12
spKt/V 1 U 0.96 (0.62–1.48) NS
rKt/V Present vs absent 0.99 (0.64–1.55) NS
1 U 0.31 (0.03–2.98) NS
nPNA 1 g1 kg1 day1 1.29 (0.80–2.10) NS
Systolic BP 1 mm Hg 1.01 (1.00–1.03) 0.028
Cholesterol 1 mg per 100 ml 1.00 (0.99–1.01) NS
X190 vs o190 mg per 100 ml 1.12 (0.69–1.82) NS
CRP 10 mg l1 1.10 (1.04–1.16) 0.0004
Albumin 1 g l1 0.92 (0.86–0.98) 0.02
X35 vs o35 g l1 0.68 (0.44–1.08) 0.10
Hemoglobin 1 g per 100 ml 0.91 (0.77–1.07) NS
Calcium 1 mg per 100 ml 0.83 (0.64–1.07) 0.15
Phosphate 1 mg per 100 ml 1.03 (0.89–1.19) NS
Calciumphosphate 1 mg2 per 100 ml2 1.00 (0.99–1.02) NS
X55 vs o55 mg2 per 100 ml2 0.91 (0.53–1.56) NS
PTH 1 ng l1 1.00 (1.00–1.00) NS
Free p-cresol 1 mg l1 1.10 (0.98–1.19) 0.10
X1.97 vs o1.97 mg l1 1.69 (1.07–2.67) 0.024
Urea 1 mg per 100 ml 1.00 (1.00–1.01) NS
b2-Microglobulin 1 mg l
1 1.05 (0.84–1.31) NS
BP, blood pressure; CRP, c-reactive protein; HD, hemodialysis; HDF, hemodiafiltration; HR, hazard ratio; LDL, low-density lipoprotein; nPNA, normalized protein nitrogen
appearance; NS, not significant; PTH, parathyroid hormone; rKt/V, residual Kt/V; spKt/V, single pool Kt/V.
P-values above 0.2 are reported as NS.
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p-cresol or p-cresyl sulfate on the endothelium (see above).
Second, the concentration of both total and free p-cresol
increases with severity of kidney disease (unpublished data).
Third, this study demonstrates, for the first time, an
association between p-cresol and CVD. However, the most
important piece of the puzzle is still missing. Indeed, as for
most novel risk factors, a demonstration that treatment of the
risk factor decreases CVD outcomes is completely lacking.
Treatment to reduce p-cresol is not feasible at present. One
strategy is to add adsorbents, such as charcoal, to the
dialysate. Using this approach, Meyer et al.40 were able to
improve the clearance of various protein-bound retention
solutes ex vivo. Mathematically, the maximal effect of
adsorbent containing dialysate is equivalent to an unlimited
increase in dialysate flow. We have recently studied the
p-cresol clearance capacity of Fractionated Plasma Separation
and Adsorption (FPSA), another adsorption-based
system. The in vivo p-cresyl sulfate percent reduction
rate was nearly two times as high as compared to a
matched high-flux hemodialysis session (unpublished data).
However, non-selective adsorption of coagulation factors
induced major coagulation disturbances,41 precluding clinical
application.
It may be worth mentioning that the relationship of free
p-cresol with overall mortality, as it was found in the original
34-month follow-up of this cohort,21 was weakened with
extended follow-up (P¼ 0.022; P¼ 0.064; P¼ 0.085 at 3, 4,
and 5 years, respectively; data not shown). This is most likely
explained by the loss of discriminative power (type II error),
and further research on a larger patient cohort is needed to
clarify this issue. From a methodological point of view, one
might question the validity of survival statistics based on a
single baseline measurement of the p-cresol level. Indeed,
considerable bias could be expected if intraindividual
variability over time was large. However, by the measurement
of three predialysis p-cresol serum levels in seven patients (a)
during 1 week and (b) 12 weeks apart, the predialysis p-cresol
serum level was found to be acceptably stable (coefficient of
variation (a) 12.1% (s.d. 2.3, median 10.5, minimum–max-
imum 2.0–19.4); (b) 12.6% (s.d. 2.3, median 9.6, mini-
mum–maximum 6.1–21.3)).21
An important new finding is that diabetic patients have
higher concentrations of both free (P¼ 0.0069) and total
p-cresol (P¼ 0.019) concentrations. Whether this is related to
particular dietary habits or is reflecting decreased well-being
of diabetic patients is not clear. Some evidence suggests
altered colonic protein fermentation, the primary source of
p-cresol, in diabetic patients. However, these findings are not
consistent.42
In conclusion, p-cresol is a novel candidate cardiovascular
risk factor in hemodialysis patients. This association is more
important in lower risk groups, such as non-diabetics.
Whether p-cresol is a modifiable cardiovascular risk factor
in hemodialysis patients remains to be proven.
MATERIALS AND METHODS
Patients
One hundred and seventy-five patients with stage V CKD were
enrolled in the original cohort. The study design has been described
previously.21 Briefly, patients on maintenance hemodialysis were
enrolled in two Belgian hemodialysis centers (University Hospital
Gasthuisberg, Leuven, and Virga Jesseziekenhuis, Hasselt) at two
inclusion dates (January 2002 and January 2003). The study was
performed according to the Declaration of Helsinki Principles and
approved by the ethics committees of the University Hospital
Leuven, Leuven, and the Virga Jesse Hospital, Hasselt. Informed
consent was obtained from all patients.
Baseline evaluation
At inclusion, blood was taken immediately before the midweek
hemodialysis session for the measurement of hemoglobin (g per
100 ml), albumin (g per 100 ml), calcium (mg per 100 ml),
phosphate (mg per 100 ml), b2-microglobulin (mg l
1), total and
free p-cresol (mg l1). To level out day-to-day variations in the
concentration of CRP (mg l1), concentrations were averaged from
45 days before to 45 days after the inclusion date (mean 3.4
measurements). To level out day-to-day variations in the measured
blood pressure, mean systolic and diastolic blood pressure measured
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Figure 2 | Kaplan-Meier curves of time to first cardiovascular
event. (a) Kaplan–Meier curve of time to first lethal or non-lethal
cardiovascular event (all patients). Patients with high (X1.97 mg l1,
n¼ 88) free p-cresol concentrations are compared to low
(o1.97 mg l1, n¼ 87) free p-cresol concentrations. Log rank
P¼ 0.022. (b) Kaplan–Meier curve of time to first lethal or non-lethal
cardiovascular event (non-diabetics, n¼ 123). Log rank P¼ 0.019.
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before start of the midweek hemodialysis session between
45 days before and 45 days after the baseline inclusion date
was calculated. Cholesterol concentrations (mg per 100 ml) were
not systematically collected at baseline. The mean of all concen-
trations measured between 180 days before and 180 days after
the baseline inclusion date was calculated. On average, 2.9
measurements were used to calculate the cholesterol concentration
in 174 patients.
Residual renal function was estimated from an interdialytic urine
collection and expressed as weekly Kt/V of urea nitrogen (rKt/V
(residual Kt/V)). Measurements were performed as part of the
baseline evaluation. Clearance (ml min1) was calculated from the
collected volume of urea nitrogen concentration in urine and in
serum. Values were recalculated to weekly clearances (l week1) by
multiplication with 10.08. The urea distribution volume was
calculated according to the Watson formula.
Albumin was measured using the bromcresol green method.
Hemoglobin, calcium, phosphate, b2-microglobulin, CRP,
and cholesterol were all measured using standard laboratory
techniques. Total and free (not bound to proteins) p-cresol serum
concentrations were measured using GC-MS (gas chromatography
mass spectrometry) as described previously. In short, the serum-
binding proteins were heat- and acid-denatured. Subsequently,
p-cresol was extracted in ethyl acetate and injected on the GC-MS
(Trace GC-MS; Thermo Finnigan, San Jose, CA, USA). 2.6-
Dimethyl-phenol was used as the internal standard. Free p-cresol
concentrations were measured in serum ultrafiltered at room
temperature using 30 000 Da molecular cutoff filters (Centrifree
UF devices; Amicon, Beverly, MA, USA). We and others have
recently demonstrated that in vivo p-cresol is almost entirely
sulfated.36–38 Both p-cresol and its conjugated metabolites were
measured by our analytical technique.37 Intra- and interassay
coefficients of variation were 3.3 and 5.3%, respectively. Values
below the limit of quantification (0.3 mg l1) were treated as
0.3 mg l1 for statistical analysis.
End point evaluation
Follow-up was extended until 31 January 2007. Events, including
cardiovascular events and cause of death, were identified by
case note review. Events were reviewed by one physician (BKIM),
blinded for the measured p-cresol concentrations. The participating
hemodialysis units both used the same electronic medical
database, in which all events were prospectively registered. To
control the accuracy of these records, all cardiology, vascular
surgery, and neurology case notes were reviewed as well. Finally,
whenever there was any doubt about a given event, the coding
physician discussed this with the treating physician of the particular
hospital.
The primary end point (first cardiovascular event) was a
composite of death from cardiac causes, non-fatal myocardial
infarction, myocardial ischemia, ischemic stroke, or new peripheral
vascular disease, whichever occurred first. Only one event per
subject was included in the analysis.
After a review of the available information, the cause of death
was classified as cardiovascular, infectious, malignant, or other.
Cardiovascular deaths included fatal myocardial infarction, sudden
death, and death due to congestive heart failure. Cases of
unobserved sudden death were considered cardiovascular death
only when other potential causes could be excluded. Otherwise, they
were classified as other cause of death.
Non-lethal cardiovascular events, including myocardial infarc-
tion, were diagnosed on the basis of the elevated levels of cardiac
enzymes and/or typical electrocardiography changes, myocardial
ischemia with typical electrocardiography changes without elevated
cardiac enzymes, and coronary intervention (thrombolysis, percu-
taneous coronary intervention, or coronary artery bypass grafting).
Ischemic stroke was defined as a neurological deficit lasting more
than 24 h. Hemorrhagic stroke was excluded from the primary end
point. Peripheral vascular disease included ischemic pain in the
lower limbs, with abnormal ankle brachial pressure index or
radiological evidence of peripheral vascular disease, ischemic
Table 3 | Multivariate Cox proportional HR analysis of time to first cardiovascular event
p-Cresol
1 mg l1 increase X1.97 vs o1.97 mg l1
Variable HR P-value Variable HR P-value
All patients
Age (years) 1.04 (1.02–1.06) o0.0001 Age 1.04 (1.02–1.06) 0.0003
CRP 1.10 (1.03–1.17) 0.003 CRP 1.11 (1.04–1.17) 0.001
Diabetes 2.35 (1.47–3.74) 0.0003 Diabetes 2.28 (1.43–3.63) 0.0005
Albumin 0.14 p-Cresol 0.085
Albumin 0.13
BP BP
Modality NS Calcium NS
p-Cresol Modality
Calcium
Non-diabetics
CRP 1.13 (1.06–1.21) 0.001 CRP 1.13 (1.06–1.20) o0.001
Age (years) 1.03 (1.00–1.06) 0.013 Age 1.03 (1.01–1.05) 0.009
p-Cresol 0.19 p-Cresol 2.04 (1.10–3.79) 0.023
Calcium Calcium
Albumin NS Albumin NS
BP BP
Modality Modality
BP, systolic blood pressure; CRP, C-reactive protein; HR, hazard ratio; NS, not significant.
Multivariate Cox proportional HR analysis, using backward elimination at PX0.2 (step 1), followed by backward elimination at PX0.05 (step 2).
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necrotic lesions, or surgical arterial intervention (excluding
arteriovenous conduits).
During the study period, 43 patients received a kidney
transplant. Five patients had a cardiovascular event before
transplantation, and the remaining 38 patients were censored.
During the study period, none of the patients were transferred to
peritoneal dialysis. Two patients were lost to follow-up owing to
transfer to a different center. One patient was censored. A third
patient was lost to follow-up but had already been censored after
receiving a renal allograft. During the study period, 59 patients were
classified as non-cardiovascular deaths, 33 of which were censored.
Statistical analysis
Continuous variables are expressed as mean (s.d.) for normally
distributed variables or median (minimum–maximum) for not
normally distributed variables. The association between the free
concentration of p-cresol and other variables was analyzed using a
Spearman rank correlation matrix (continuous variables) and
ANOVA (dichotomous variables).
Time to first cardiovascular event analysis was performed using
Cox proportional hazards analysis. The relative risk of a new
cardiovascular event was expressed as a hazard ratio. The
Kaplan–Meier method was used to estimate cumulative incidence
of the primary end point. To compare the strength of the association
between p-cresol and the primary end point relative to other
frequently used cardiovascular risk factors, p-cresol was tested in
multivariate analysis, including all risk factors significant at the
Pp0.2 level on univariate analysis (age, diabetes, treatment
modality, systolic blood pressure, albumin, calcium, CRP, and free
p-cresol). In the first step, the most representative variables were
selected using backward elimination (Pp0.20). The selected subset
of variables was then evaluated using backward elimination
(Pp0.05) to define the best model to explain the outcome variable.
A grouped analysis of diabetics and non-diabetics was performed
using the same set of variables. For statistics, SAS (version 9.1, SAS
Institute, Cary, NC, USA) and SPSS (version 15.0, Chicago, IL,
USA) software packages have been used.
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